Explore More: Innovation in Immunotherapy
Duane Mitchell, M.D., Ph.D., co-director of UF’s Preston A. Wells Jr. Center for Brain Tumor Therapy and head of the Cancer Therapeutics & Immuno-Oncology program at the UF Health Cancer Center, presented a conversation about the use of immunotherapy to treat brain cancers on Monday, Feb. 13 at 6 p.m. in the Pugh Hall Ocora.
Mitchell came to UF from Duke University in 2013 to lead a comprehensive brain tumor program that focuses on stimulating immune responses against malignant brain tumor cells. Last year, Mitchell and his team had one of the most cited papers in the field for their work on glioblastomas, the deadliest brain cancer in adults, with an average survival time of 15 to 18 months. The research conducted at UF and Duke has shown that patients who received an enhanced cancer vaccine had a significant improvement in overall survival length. The team is also known for its focus on pediatric cancer. Mitchell is leading a multi-institutional immunotherapy trial for children with recurrent medulloblastoma, the most common type of pediatric malignant brain tumor.
To learn more about the work of Mitchell and his colleagues, click here.
The event was co-sponsored by UF’s Explore research magazine, the Office of Research and the Bob Graham Center for Public Service.